USA - NASDAQ:SINT - US8293927039 - Common Stock
The current stock price of SINT is 3.49 USD. In the past month the price increased by 4.18%. In the past year, price decreased by -29.64%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.06 | 226.31B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.5 | 195.98B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.49 | 150.78B | ||
| SYK | STRYKER CORP | 27.34 | 137.68B | ||
| BDX | BECTON DICKINSON AND CO | 13.24 | 54.74B | ||
| IDXX | IDEXX LABORATORIES INC | 53.05 | 53.52B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.97 | 49.75B | ||
| RMD | RESMED INC | 24.72 | 35.71B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.39 | 32.25B | ||
| PODD | INSULET CORP | 71.78 | 23.09B | ||
| DXCM | DEXCOM INC | 31.45 | 22.94B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.96 | 17.56B |
SINTX Technologies, Inc. is a ceramics company, which engages in the development and commercialization of silicon nitride for medical and non-medical applications. The company is headquartered in Salt Lake City, Utah and currently employs 20 full-time employees. The company went IPO on 2014-02-11. The company is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. The company has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. The company manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah.
SINTX TECHNOLOGIES INC
1885 West 2100 Street
Salt Lake City UTAH 84119 US
CEO: B. Sonny Bal
Employees: 20
Phone: 18018393516
SINTX Technologies, Inc. is a ceramics company, which engages in the development and commercialization of silicon nitride for medical and non-medical applications. The company is headquartered in Salt Lake City, Utah and currently employs 20 full-time employees. The company went IPO on 2014-02-11. The company is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. The company has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. The company manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah.
The current stock price of SINT is 3.49 USD. The price increased by 10.79% in the last trading session.
SINT does not pay a dividend.
SINT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
SINTX TECHNOLOGIES INC (SINT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.8).
SINTX TECHNOLOGIES INC (SINT) has a market capitalization of 12.53M USD. This makes SINT a Nano Cap stock.
SINTX TECHNOLOGIES INC (SINT) will report earnings on 2026-03-17.
ChartMill assigns a technical rating of 1 / 10 to SINT. When comparing the yearly performance of all stocks, SINT is a bad performer in the overall market: 77.84% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to SINT. While SINT seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SINT reported a non-GAAP Earnings per Share(EPS) of -6.8. The EPS increased by 92.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -136.42% | ||
| ROE | -314.54% | ||
| Debt/Equity | 0 |
7 analysts have analysed SINT and the average price target is 25.5 USD. This implies a price increase of 630.66% is expected in the next year compared to the current price of 3.49.
For the next year, analysts expect an EPS growth of 82.02% and a revenue growth -67.16% for SINT